KT-621 achieved deep STAT6 degradation across both the 100 mg and 200 mg dose groups tested, with median reductions of 94% and 98% in skin and ...

Kymera Therapeutics has now reported top-line data from its BroADen Phase 1b trial of KT-621, a once-daily oral STAT6 degrader, in patients with moderate to severe atopic dermatitis, alongside ...

Patients in 200 mg BID cohort had median progression free survival of 6.2 months and median overall survival of 28.1 months, comparing favorably ...

Kymera shows strong KT-621 Phase 1b efficacy, solid safety, platform validation, cash runway and growth potential in key ...

Kymera Therapeutics (NASDAQ:KYMR) jumped 16% on Monday after the company reported promising early-stage clinical results for ...

Children saw improvements in their atopic dermatitis with tapinarof regardless of their atopic comorbidities, according to ...

Itchy and dry skin. Rashes and skin lesions affecting face, behind the knees, on the hands and feet and inside the folds of the elbows. The lesions due to scratching may be red, swollen, with cracking ...

Early trial results show stapokibart improves paediatric atopic dermatitis with good tolerability. Find out more about its ...

If you have atopic dermatitis, the most common form of eczema, you may have noticed dark patches or light spots on your skin. This discoloration, which tends to linger after a flare, can be very ...

Investing.com -- Kymera Therapeutics (NASDAQ:KYMR) stock surged 16% after the company announced positive results from its Phase 1b clinical trial of KT-621, an oral STAT6 degrader, in patients with ...